PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE ATTORNEY WORK PRODUCT
MEMORANDUM
TO: Special Committee of the Board of Directors of Penterra Pharmaceuticals Corp. — Diane Prescott (Chair), James Okafor, Dr. Helen Ng
FROM: Renata Vasquez, Partner, and Sophie Tremblay, Associate, Calderwood & Harkness LLP
DATE: June 8, 2023
RE: Delaware Law Governing Interested Director Transactions — Proposed Acquisition of Caliston BioSciences, Inc.
Matter No.: 1025-00006 (Project Coriander)
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to provide the Special Committee of the Board of Directors of Penterra Pharmaceuticals Corp. ("Penterra" or the "Company") with a comprehensive analysis of the Delaware legal framework governing the proposed acquisition of Caliston BioSciences, Inc. ("Caliston"), a transaction in which the Company's Chairman and Chief Executive Officer, Dr. Marcus Hale, holds a 28.5% equity interest in the target. This memorandum addresses the key doctrines of Delaware corporate law applicable to the proposed transaction: Section 144 of the Delaware General Corporation Law (the "DGCL"), the entire fairness doctrine as developed through decades of Delaware Chancery and Supreme Court jurisprudence, and the framework established by the Delaware Supreme Court in Kahn v. M&F Worldwide Corp., 88 A.3d 635 (Del. 2014) (the "MFW framework"). Each of these doctrines operates at a distinct level of the analytical framework, and together they define both the legal risks confronting the Company and the procedural safeguards available to the Special Committee to mitigate those risks.
Because Dr. Hale stands on both sides of this transaction — serving as Penterra's Chairman and CEO on the buyer side and holding a substantial 28.5% equity interest in Caliston on the seller side — the proposed acquisition constitutes a related-party transaction subject to heightened judicial scrutiny under Delaware law. Dr. Hale's personal financial stake in the transaction is significant: at the currently proposed aggregate equity value of $925 million, his implied proceeds would be approximately $263,625,000, representing an implied gain of approximately $221,625,000 over his original $42 million investment. His interest is not merely theoretical; it is a concrete, quantifiable financial benefit that directly conflicts with his fiduciary duties to Penterra stockholders.
In addition to Dr. Hale's conflict, Angela Whitmore, a non-independent Penterra director and Executive Vice President of Commercial Operations, is the spouse of Dr. Evan Whitmore, who serves as Caliston's Head of Clinical Development and as a member of the Caliston board of directors. This spousal relationship creates an additional, independent conflict nexus that further underscores the need for robust procedural protections.
Notwithstanding these conflicts, Delaware law provides a well-established roadmap for the Special Committee to protect both the Company and its stockholders. If proper procedural protections are implemented and rigorously adhered to, the Special Committee can position the transaction for review under the deferential business judgment standard of review rather than the exacting entire fairness standard. Specifically, compliance with all six conditions of the MFW framework — including conditioning the transaction from the outset on both Special Committee approval and a majority-of-the-minority stockholder vote — offers the strongest pathway to business judgment review, which would effectively insulate the transaction from judicial challenge absent a showing of waste or bad faith.
This memorandum is prepared in connection with, and references, the Board Resolution dated June 2, 2023, adopted by the unanimous vote of the six independent directors of Penterra (with Dr. Hale, Ms. Whitmore, and Mr. Tusk recused), which established the Special Committee with sole and exclusive authority to evaluate, negotiate, recommend, or decline the proposed transaction. Calderwood & Harkness LLP was engaged on June 2, 2023 as independent legal counsel to the Special Committee pursuant to that resolution.
The sections that follow present: (i) the factual background relevant to the legal analysis; (ii) an analysis of DGCL §144 and its application to the proposed transaction; (iii) a detailed treatment of the entire fairness doctrine; (iv) a comprehensive discussion of the MFW framework and its application; (v) specific issues requiring attention; (vi) the applicability of MFW outside the controlling-stockholder context; and (vii) our procedural recommendations for the Special Committee.
II. Factual Background Relevant to the Legal Analysis
The following factual summary is based on information provided to Calderwood & Harkness LLP through the Company's regular outside counsel, Alcott, Barringer & Cole LLP, as well as materials reviewed in connection with the formation of the Special Committee. We present these facts to establish the analytical foundation for the legal discussion that follows.
A. The Proposed Transaction
Penterra proposes to acquire 100% of the outstanding equity of Caliston via a one-step merger, pursuant to which Caliston would merge with and into a wholly owned subsidiary of Penterra, with Caliston surviving as a wholly owned subsidiary. Caliston is a privately held, Delaware-incorporated, clinical-stage biopharmaceutical company headquartered at 88 Harbor Point Road, Cambridge, Massachusetts 02142.
Caliston's lead clinical asset is CLT-4019, a selective CDK4/6 inhibitor currently in Phase 2b clinical development for the treatment of HR+/HER2– metastatic breast cancer. The Investigational New Drug Application for CLT-4019 (IND 158429) was filed with the U.S. Food and Drug Administration in March 2020. Phase 2b topline data are expected in the fourth quarter of 2023. In addition to CLT-4019, Caliston's pipeline includes CLT-5227 and CLT-6034, both of which are in preclinical development.
Caliston's last private valuation was $680 million on a post-money basis, established in connection with its Series C financing round in October 2021. The company is pre-commercial, having reported no revenue for fiscal year 2022 (FY2022). Its FY2022 net cash burn was $78.4 million, and as of March 31, 2023, Caliston reported cash on hand of $112.6 million, providing an estimated operating runway through the first quarter of 2025. The company has 94 employees and has raised a total of $347 million in equity financing across its Seed, Series A, Series B, and Series C rounds.
B. Dr. Hale's Interests in Caliston
Dr. Marcus Hale, Penterra's Chairman and CEO, holds a 28.5% equity interest in Caliston. He acquired this interest through personal investments totaling $42 million, made across the Seed, Series A, and Series B rounds. Dr. Hale did not participate in the Series C round.
At the currently proposed aggregate equity value of $925 million, Dr. Hale's implied proceeds from the transaction would be $263,625,000, calculated as 28.5% multiplied by $925 million. His implied gain on the investment would be approximately $221,625,000, representing the difference between his implied proceeds and his original $42 million investment cost basis. This implied gain represents a return of approximately 5.28 times his invested capital.
In addition to his equity interest, Dr. Hale has served as a non-voting board observer at Caliston since 2018. In that capacity, he has attended 14 of the 16 Caliston board meetings held during his tenure as observer, providing him with significant insight into Caliston's clinical progress, strategic direction, financial condition, and internal deliberations.
Notably, Dr. Hale did not disclose his Caliston investment to the Penterra board of directors until February 14, 2023, the date on which he first proposed the acquisition of Caliston. This delayed disclosure is discussed further in Section VI.A below.
Dr. Hale's holdings in Penterra consist of approximately 2,140,000 shares of Penterra common stock, representing approximately 1.8% of the Company's approximately 121.4 million shares outstanding. His FY2022 total compensation from Penterra was approximately $5.8 million, consisting of $3.2 million in base salary and $2.6 million in equity awards and other compensation.
C. Angela Whitmore's Relationship
Angela Whitmore serves as a director of Penterra and as the Company's Executive Vice President of Commercial Operations. Ms. Whitmore is classified as non-independent under both Delaware law and NYSE listing standards. She is the spouse of Dr. Evan Whitmore, who serves as Caliston's Head of Clinical Development and as a member of the Caliston board of directors. Dr. Evan Whitmore holds an equity interest in Caliston through the management equity pool and would receive merger consideration in connection with the proposed transaction.
This spousal relationship creates an additional conflict of interest that is independent of, and additive to, Dr. Hale's conflict. Ms. Whitmore's financial interest in the outcome of the transaction — through her husband's receipt of merger consideration and his continued employment relationship with Caliston (and, post-closing, Penterra) — requires her exclusion from the Special Committee and recusal from all board deliberations concerning the transaction.
D. Other Caliston Stockholders
Caliston's capitalization table includes the following significant equity holders in addition to Dr. Hale:
• Ridgeline Ventures, LP holds a 22.3% equity interest, acquired as the lead investor in the Series C round. Its managing partner is Ava Lindström.
• Meridian Life Sciences Fund III, LP holds an 18.7% equity interest, having served as the lead investor in the Series B round. Its managing partner is Tomás Reyes.
• Caliston founders and management collectively hold 30.5% of the equity through the management equity pool. This includes Dr. Nadia Sorensen, Caliston's Chief Executive Officer, who holds a 14.2% interest; Dr. Raj Malhotra, Caliston's Chief Scientific Officer, who holds a 9.8% interest; and other management team members who collectively hold 6.5%.
The remaining equity interests are held by earlier-stage investors and other participants in Caliston's financing history. For purposes of the Caliston stockholder approval required to consummate the merger, approval by written consent of holders of a majority of the outstanding equity is expected to be obtained from the combination of Dr. Hale (28.5%), Ridgeline Ventures (22.3%), and one or more additional holders, which together would exceed the majority threshold.
E. The Penterra Board Composition and Recused Members
The Penterra board of directors consists of nine members, of whom six are classified as independent under applicable NYSE listing standards and Delaware common law. Three directors have been identified as conflicted and have been recused from all deliberations and voting with respect to the proposed transaction:
• Dr. Marcus Hale — Chairman and CEO of Penterra; interested party by virtue of his 28.5% equity interest in Caliston, board observer role at Caliston, and personal financial stake of approximately $263,625,000 in the transaction proceeds.
• Angela Whitmore — Director and EVP, Commercial Operations; conflicted by virtue of her spousal relationship with Dr. Evan Whitmore, a Caliston board member and executive who holds equity in Caliston and would receive merger consideration.
• Raymond Tusk — Director; classified as non-independent by virtue of his status as a Hale appointee and his personal and professional relationship with Dr. Hale.
The Special Committee consists of three independent directors:
• Diane Prescott (Chair) — Former Chief Executive Officer of Windbridge Health Systems, Inc. Ms. Prescott has no material relationships with Caliston, Dr. Hale, or any Caliston stockholder or advisor.
• James Okafor — Retired managing director of Fielding Capital Partners, LLC. Mr. Okafor has no material relationships with Caliston, Dr. Hale, or any Caliston stockholder or advisor.
• Dr. Helen Ng — Professor of Pharmacology at Wexford University and former member of an FDA advisory committee. Dr. Ng has no material relationships with Caliston, Dr. Hale, or any Caliston stockholder or advisor.
The independence of each Special Committee member has been confirmed through the director independence questionnaire process conducted by Alcott, Barringer & Cole LLP in consultation with Calderwood & Harkness LLP.
F. Transaction Economics (for Context)
The proposed transaction economics, as currently structured, are as follows:
For context, Penterra reported FY2022 revenue of $1.836 billion, FY2022 EBITDA of $412 million, and had a market capitalization of approximately $4.72 billion as of the date of this memorandum. The Company's cash on hand at FY2022 year-end was $892 million, and its total outstanding debt was approximately $1.35 billion.
The cash consideration of $693,750,000 is proposed to be funded from two sources: $400 million from cash on hand and $293.75 million from a draw on Penterra's existing $1.5 billion revolving credit facility with Greystone National Bank, N.A. (SOFR + 150 basis points; maturity March 2026; $1.1 billion undrawn as of June 1, 2023).
Under NYSE Listed Company Manual rules, Penterra stockholder approval is required for the issuance of Penterra common stock in connection with the transaction, as the 5,903,497 shares to be issued represent significantly more than 1% of Penterra's outstanding shares. On the Caliston side, stockholder approval of the merger by written consent of holders of a majority of the outstanding equity will be required.
G. Procedural History to Date
The following timeline summarizes the key procedural events leading to the engagement of Calderwood & Harkness LLP and the preparation of this memorandum:
• February 14, 2023: Dr. Hale discloses his 28.5% equity interest in Caliston to the Penterra board of directors for the first time and proposes that Penterra explore the acquisition of Caliston.
• March 8, 2023: The Penterra board meets to discuss the potential conflicts of interest arising from Dr. Hale's Caliston investment and his dual role in the proposed transaction. The board resolves to consider the formation of a special committee of independent directors to evaluate the transaction.
• April 12, 2023: The board retains Alcott, Barringer & Cole LLP (Victoria Shen, lead partner) as outside governance counsel to advise on the process for establishing a special committee and implementing appropriate procedural protections.
• May 15, 2023: The board approves the formation of the Special Committee, effective upon the engagement of independent legal counsel for the Special Committee.
• June 2, 2023: The Special Committee is formally constituted. Calderwood & Harkness LLP is engaged as independent legal counsel to the Special Committee. The Board Resolution is adopted by the unanimous vote of the six independent directors (Dr. Hale, Ms. Whitmore, and Mr. Tusk recused), granting the Special Committee sole and exclusive authority to evaluate, negotiate, recommend, or decline the proposed transaction. Concurrently, Dr. Hale executes a Voting and Recusal Agreement committing to recuse himself from all board deliberations concerning the transaction and to abstain from voting on the merger at the board level.
• June 16, 2023: Thorngate Partners LLC is engaged as independent financial advisor to the Special Committee (engagement reference 1018-00003), following a conflicts clearance process.
No substantive price or economic negotiations have been conducted between Penterra and Caliston as of the date of this memorandum. Dr. Hale's initial proposal on February 14, 2023, included a preliminary expression of interest at the $925 million aggregate equity value with the consideration mix described above, but this proposal has not been the subject of negotiation or counter-proposal between the parties. All future negotiations will be conducted by and through the Special Committee, acting through its independent advisors.
III. Delaware General Corporation Law §144 — Interested Director Transactions
A. Statutory Text and Purpose
Section 144 of the Delaware General Corporation Law provides the foundational statutory framework governing transactions between a corporation and an entity in which one or more of the corporation's directors or officers has a financial interest. The purpose of §144 is to provide a safe harbor that protects interested director transactions from automatic voidability based solely on the existence of the director's interest. Prior to the enactment of §144, the common law in many jurisdictions treated any transaction in which a director had a personal financial interest as voidable at the election of the corporation or its stockholders, regardless of the transaction's substantive fairness.
Section 144 provides that a contract or transaction between a corporation and one or more of its directors or officers, or between a corporation and any other corporation, partnership, association, or other organization in which one or more of its directors or officers are directors or officers, or have a financial interest, shall not be void or voidable solely for such reason, or solely because the director or officer is present at or participates in the meeting of the board or committee which authorizes the contract or transaction, or solely because any such director's or officer's votes are counted for such purpose, if one of the following three conditions is satisfied:
(1) Disinterested Board or Committee Approval (§144(a)(1)): The material facts as to the director's or officer's relationship or interest and as to the contract or transaction are disclosed to or are known by the board of directors or the committee, and the board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum.
(2) Stockholder Approval (§144(a)(2)): The material facts as to the director's or officer's relationship or interest and as to the contract or transaction are disclosed to or are known by the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders.
(3) Intrinsic Fairness (§144(a)(3)): The contract or transaction is fair as to the corporation as of the time it is authorized, approved, or ratified, by the board of directors, a committee thereof, or the stockholders.
These three safe harbors operate independently; satisfaction of any one is sufficient to prevent automatic voidability under the statute. However, as discussed below, satisfaction of §144 alone does not immunize a transaction from challenge on fiduciary duty grounds. The statute addresses only the threshold question of voidability and does not define the applicable standard of judicial review.
B. Application to the Proposed Transaction
Dr. Hale is clearly an "interested director" within the meaning of §144 by virtue of his 28.5% equity interest in Caliston and his personal financial stake of approximately $263,625,000 in the transaction proceeds. His interest is not incidental or de minimis; it represents a substantial personal financial benefit that is distinct from any benefit that would accrue to Penterra stockholders generally. Moreover, his role as a non-voting board observer at Caliston since 2018, during which he attended 14 of 16 board meetings, further demonstrates the depth and materiality of his involvement with and interest in the target company.
Angela Whitmore's spousal relationship with Dr. Evan Whitmore creates an additional interest within the meaning of §144. Although her interest is arguably derivative — she does not hold a direct equity stake in Caliston — Delaware courts have consistently treated close familial relationships, and particularly spousal relationships, as creating material interests that can compromise a director's independence and impartiality. See, e.g., Beam ex rel. Martha Stewart Living Omnimedia, Inc. v. Stewart, 845 A.2d 1040, 1051-52 (Del. 2004) (discussing the significance of personal relationships in assessing director independence); In re Ostrander Corporation. Derivative Litigation, 824 A.2d 917, 937-38 (Del. Ch. 2003) (examining whether personal connections compromise independent judgment). Dr. Evan Whitmore's dual role as a Caliston executive and board member, combined with his equity interest in Caliston through the management pool, means that he stands to benefit directly from the transaction, and Ms. Whitmore's financial and personal interests are materially aligned with his.
It is critical for the Special Committee to understand that §144 is necessary but not sufficient to protect the transaction from challenge. Delaware courts have consistently held that compliance with §144 removes only the risk that the transaction will be deemed automatically void or voidable solely because of the director's interest. Compliance with §144 does not, by itself, establish that the transaction satisfies the fiduciary duties owed by the directors to the corporation and its stockholders. As the Court of Chancery stated in Benihana of Tokyo, Inc. v. Benihana, Inc., 906 A.2d 114, 120 (Del. 2006), "Section 144 does not, by itself, validate an interested transaction. It simply removes the common-law defense of voidability and shifts the analysis to the applicable fiduciary standard."
In practice, compliance with §144(a)(1) — approval by a properly informed committee of disinterested directors acting in good faith — removes the voidability risk and transitions the analysis to the question of which standard of judicial review applies to the fiduciary duty claims. That standard of review, in turn, depends on the procedural protections employed by the board and its committee, as discussed in Sections IV and V below.
C. Disclosure Obligations Under §144
The disclosure requirements under §144(a)(1) are rigorous. All material facts regarding Dr. Hale's relationship with Caliston and his interest in the proposed transaction must be fully disclosed to the Special Committee. At minimum, the following information must be disclosed and documented in the Special Committee's records:
(a) The nature and extent of Dr. Hale's equity interest in Caliston (28.5%);
(b) Dr. Hale's original acquisition cost ($42 million across the Seed, Series A, and Series B rounds), including the timing and amounts of each investment;
(c) Dr. Hale's implied proceeds from the transaction ($263,625,000 at the proposed $925 million aggregate equity value);
(d) Dr. Hale's implied gain ($221,625,000);
(e) Dr. Hale's role as a non-voting board observer at Caliston since 2018, including his attendance at 14 of 16 Caliston board meetings;
(f) The timing of Dr. Hale's investments in Caliston (Seed, Series A, and Series B rounds) and his non-participation in the Series C round;
(g) Dr. Hale's failure to disclose his Caliston interest to the Penterra board until February 14, 2023, despite having held the investment since the Seed round;
(h) Angela Whitmore's spousal relationship with Dr. Evan Whitmore, including Dr. Evan Whitmore's roles as Caliston's Head of Clinical Development and as a Caliston board member, and his equity interest in Caliston through the management pool;
(i) Raymond Tusk's status as a Hale appointee and his classification as non-independent; and
(j) Any other material facts known to the Company regarding the relationships between Penterra directors or officers and Caliston or its stockholders, directors, officers, or advisors.
We recommend that the Company's General Counsel, Lawrence Whittaker, be directed (through the Special Committee) to compile a comprehensive written disclosure package documenting all of these facts. This package should be formally presented to the Special Committee and its receipt acknowledged in the minutes of a Special Committee meeting. The disclosure package should be maintained as part of the Project Coriander segregated document management workspace.
We note, however, that because Mr. Whittaker serves as General Counsel to the Company (and thus reports to Dr. Hale), the Special Committee should exercise caution in relying on Mr. Whittaker as the sole source of disclosure. Calderwood & Harkness LLP and Thorngate Partners LLC should independently verify the completeness and accuracy of the disclosures through their own due diligence.
IV. The Entire Fairness Doctrine
A. Overview
When a transaction involves a conflict of interest on the part of a director who is also a controlling stockholder or who otherwise stands on both sides of a transaction, Delaware courts apply the "entire fairness" standard of review — the most exacting standard in Delaware corporate law. The entire fairness standard requires that the defendants demonstrate that the transaction was entirely fair to the corporation and its minority stockholders. The doctrine traces its roots to Weinberger v. UOP, Inc., 457 A.2d 701 (Del. 1983), in which the Delaware Supreme Court articulated the two-pronged test that continues to govern entire fairness analysis.
Entire fairness comprises two interrelated components:
(1) Fair Dealing — the process by which the transaction was initiated, structured, negotiated, disclosed to the directors and stockholders, and approved; and
(2) Fair Price — the economic and financial considerations of the proposed transaction, including the value of the assets, the market and intrinsic value of the company, and other factors bearing on the adequacy of the consideration.
The Delaware Supreme Court has emphasized that these two components are not independent, bifurcated tests. Rather, the court examines the transaction as a whole, considering the totality of the circumstances. A deficiency in one component may be offset, to some degree, by strength in the other, but the ultimate inquiry is whether the transaction, viewed in its entirety, was fair. As the Court stated in Weinberger, "the test for fairness is not a bifurcated one as between fair dealing and fair price. All aspects of the issue must be examined as a whole since the question is one of entire fairness." 457 A.2d at 711.
B. Fair Dealing
Fair dealing encompasses the manner in which the transaction was initiated, structured, negotiated, disclosed, and approved. It is a process-oriented inquiry that examines whether the procedural aspects of the transaction were consistent with the fiduciary duties owed to the minority stockholders. Courts consider the following key elements in assessing fair dealing:
• Timing: When was the transaction initiated, and was the timing calculated to disadvantage the minority?
• Independence of Negotiators: Were the persons negotiating on behalf of the corporation independent of the interested party? Were they free from conflicts and able to exercise genuine independent judgment?
• Structure of the Process: Was the process structured to ensure arm's-length bargaining? Was a special committee formed? Was the committee empowered to retain independent advisors and to reject the transaction?
• Completeness of Disclosure: Were all material facts disclosed to the decision-makers? Were any material facts withheld or presented in a misleading manner?
• Exclusion of Interested Parties: Were the interested parties excluded from the negotiation and deliberation process?
As applied to the proposed transaction, the Special Committee must be able to demonstrate all of the following in order to establish fair dealing:
First, that Dr. Hale was excluded from all deliberations concerning the transaction. The June 2, 2023 Board Resolution formally establishes this exclusion, and the Voting and Recusal Agreement executed by Dr. Hale on that date provides a contractual commitment to recuse from board deliberations and abstain from voting on the merger at the board level. Additionally, the Information Barrier Policy, implemented concurrently with the Board Resolution, restricts Dr. Hale's access to information concerning the Special Committee's deliberations, advisor communications, and negotiating positions. Compliance with these restrictions must be maintained throughout the process.
Second, that Angela Whitmore and Raymond Tusk were likewise excluded from all deliberations and decision-making concerning the transaction. Both have been recused under the Board Resolution, and the Information Barrier Policy applies to them as well.
Third, that the Special Committee retained truly independent advisors. Calderwood & Harkness LLP was engaged as independent legal counsel following a conflicts clearance that confirmed no material relationships with Caliston, Dr. Hale, Ridgeline Ventures, Meridian Life Sciences Fund III, or any other party to the transaction. Thorngate Partners LLC was subsequently engaged as independent financial advisor on June 16, 2023, following a similar conflicts clearance process (engagement reference 1018-00003). Critically, Alcott, Barringer & Cole LLP, Penterra's regular outside counsel, was recused from advising the Special Committee on the merits of the transaction. While Alcott Barringer played a valuable role in advising on the governance process for establishing the Special Committee, its ongoing relationship with Penterra management (including Dr. Hale) makes it unsuitable to serve as counsel to the Special Committee in evaluating the transaction itself.
Fourth, that the Special Committee had genuine authority to reject the transaction and to explore alternatives. The Board Resolution grants the Special Committee sole and exclusive authority to decline the transaction, and the Special Committee Charter authorizes the Committee to conduct a market check to evaluate whether superior alternatives exist. This "say no" power is a critical element of fair dealing, as it ensures that the Committee is not merely a rubber stamp for a predetermined outcome.
Fifth, that negotiation was conducted at arm's length, with the Special Committee acting through its own advisors rather than through Penterra management or Dr. Hale. All communications with Caliston and its advisors (Whitfield Graves LLP as legal counsel and Fendowell Sinclair & Co. as financial advisor) should be conducted through Calderwood & Harkness LLP and Thorngate Partners LLC. Under no circumstances should Dr. Hale or any member of Penterra management acting at his direction participate in or influence the negotiation process.
Sixth, that all material information was provided to and considered by the Special Committee. This includes Thorngate Partners' valuation analyses, Caliston's financial and clinical data, the terms of the proposed merger agreement, and any other information bearing on the fairness of the transaction.
C. Fair Price
Fair price relates to the economic and financial considerations of the proposed transaction, including asset valuation, market value, earnings, future prospects, and any other elements that affect the intrinsic or inherent value of the target. In the context of a cash-and-stock acquisition of a clinical-stage biopharmaceutical company, the fair price analysis will necessarily rely heavily on discounted cash flow modeling, comparable transaction analysis, and assessment of the risk-adjusted value of the target's clinical pipeline.
Thorngate Partners LLC's independent valuation analyses, which are currently in progress, will serve as the primary evidentiary basis for the Special Committee's assessment of fair price. Based on preliminary indications provided by Thorngate Partners, the valuation ranges are as follows:
Key assumptions underlying the DCF analyses include a weighted average cost of capital (WACC) of 12.5% and a terminal growth rate of 2.0%. These assumptions reflect the risk profile of a clinical-stage biopharmaceutical company with a lead asset in Phase 2b development.
The proposed aggregate equity value of $925 million falls within or near the midpoint of these ranges. The contingent value right (CVR) of $125 million, payable upon FDA approval of CLT-4019 by December 31, 2026, provides additional upside to Caliston stockholders contingent on the successful regulatory outcome of the lead asset, bringing the maximum aggregate transaction value to $1,050 million.
The 36.03% premium to the October 2021 Series C post-money valuation of $680 million is a relevant data point in assessing fair price. However, the Special Committee should note that the Series C occurred approximately twenty months prior to the proposed transaction, and Caliston's clinical program has progressed materially during the intervening period (Phase 2b enrollment and data generation for CLT-4019), while its cash position has diminished through ongoing operations ($78.4 million net cash burn in FY2022). The premium analysis must therefore be contextualized against the evolution of Caliston's value drivers and risk profile since the Series C.
The Special Committee should ultimately satisfy itself that the proposed price was the product of genuine arm's-length bargaining, informed by independent financial advice, and that the price falls within a range of fairness as determined by Thorngate Partners' analyses. The Special Committee is not required to obtain the lowest possible price; rather, it must determine that the price is fair to Penterra and its stockholders, taking into account the strategic rationale for the acquisition, the risk-adjusted value of Caliston's pipeline, and the competitive landscape for clinical-stage oncology assets.
D. Burden of Proof Under Entire Fairness
The allocation of the burden of proof under the entire fairness standard is a critical procedural consideration. The default rule in Delaware is as follows: when a director who stands on both sides of a transaction is involved, the burden of proving entire fairness rests on the defendant directors. This means that, in the absence of procedural protections, Dr. Hale (and potentially the other director defendants) would bear the burden of demonstrating that the transaction was entirely fair — both as to dealing and as to price — if the transaction were challenged in litigation.
However, the burden of proof may be shifted to the plaintiff in certain circumstances. Specifically, if the transaction is approved by a well-functioning committee of independent, disinterested directors, or if the transaction is approved by an informed, uncoerced vote of a majority of the disinterested stockholders, the burden of proof shifts from the defendants to the plaintiff. Under this burden-shifting framework, the plaintiff must demonstrate that the transaction was not entirely fair. While this shift is procedurally significant — it is considerably more difficult for a plaintiff to carry the burden of proving unfairness than for a defendant to carry the burden of proving fairness — it is important to understand that the standard of review itself does not change. The entire fairness standard continues to apply; only the party bearing the burden changes.
This is a critical distinction that bears on the MFW framework discussed below. Burden shifting (placing the burden on the plaintiff while retaining entire fairness review) is distinct from standard shifting (moving from entire fairness review to the more deferential business judgment standard). Burden shifting is available when one procedural protection is present (either an independent committee or a minority vote). Standard shifting — which effectively eliminates the entire fairness inquiry and replaces it with the business judgment standard — requires both procedural protections, as established by the MFW framework.
V. The MFW Framework — Pathway to Business Judgment Review
A. Overview of the MFW Decision
In Kahn v. M&F Worldwide Corp., 88 A.3d 635 (Del. 2014), the Delaware Supreme Court established a landmark framework under which a conflicted transaction may receive deferential business judgment review — rather than the searching entire fairness review — provided that specific procedural conditions are satisfied from the inception of the transaction process. The MFW decision represented a significant development in Delaware law because it provided, for the first time, a clear pathway by which a conflicted controller (or, by extension, an interested party) could obtain the most protective standard of review available under Delaware law, thereby substantially reducing the litigation risk associated with the transaction.
Although MFW arose in the specific context of a controlling stockholder squeeze-out transaction, Delaware courts — including both the Court of Chancery and the Supreme Court — have applied its principles more broadly to interested director transactions and other contexts in which a fiduciary stands on both sides of a transaction. The applicability of MFW to the present transaction (in which Dr. Hale is not a controlling stockholder of Penterra but holds a controlling interest in the target) is discussed in Section VII below.
Business judgment review is the most deferential standard of review in Delaware corporate law. Under the business judgment rule, a court will not second-guess the substantive merits of a board's (or committee's) business decision so long as the directors acted on an informed basis, in good faith, and in the honest belief that the action taken was in the best interests of the corporation. To overcome business judgment review, a plaintiff must demonstrate that the transaction constituted "waste" — i.e., that no reasonable person could find that the transaction was fair — or that the directors acted in bad faith or with a disabling conflict of interest. This is an extraordinarily high bar, and transactions that receive business judgment review are, as a practical matter, virtually unassailable absent egregious facts.
B. The Six MFW Conditions
The Delaware Supreme Court in MFW established six conditions, all of which must be satisfied in order for the standard of review to shift from entire fairness to business judgment:
Condition 1 — Ab Initio Conditioning. The controlling stockholder or interested party must condition the transaction, from the beginning (i.e., before any substantive economic negotiations occur), on both (a) the approval of a fully empowered, independent special committee of the board of directors and (b) the approval of a majority of the minority (i.e., disinterested) stockholders. This dual conditioning must be in place ab initio — that is, from the outset of the process. It is not sufficient to impose these conditions after substantive negotiations have begun or after economic terms have been discussed.
Condition 2 — Independence. The special committee must be composed of directors who are independent of the interested party. Independence requires that the committee members have no material financial, personal, or professional relationships with the interested party that would compromise their ability to exercise genuine independent judgment.
Condition 3 — Empowerment. The special committee must be empowered to freely select its own legal and financial advisors and must have the unequivocal authority to reject the proposed transaction. The committee's authority must not be limited to making a recommendation; it must have definitive decision-making power, including the power to say "no."
Condition 4 — Due Care. The special committee must satisfy its duty of care in evaluating and negotiating the transaction. This requires a thorough, informed process that includes independent due diligence, engagement of qualified advisors, receipt of a fairness opinion, and genuine arm's-length negotiation of the transaction terms.
Condition 5 — Informed, Uncoerced Minority Vote. The vote of the disinterested stockholders must be fully informed and free from coercion. This requires comprehensive disclosure of all material facts in the proxy statement, including the conflicts of interest, the special committee's process, the financial advisor's analyses and fairness opinion, and the terms of the transaction.
Condition 6 — No Structural Coercion. There must be no structural coercion that impacts the integrity of either the special committee process or the stockholder vote. Structural coercion can arise from range sources, including implicit threats regarding the interested party's future conduct if the transaction is not approved, or structural features of the transaction that disadvantage stockholders who vote against the deal.
C. Application to the Proposed Transaction
Condition 1 — Ab Initio Conditioning
The ab initio requirement is the most critical and most commonly litigated of the six MFW conditions. Delaware courts have been exacting in their insistence that the dual conditions — special committee approval and majority-of-the-minority vote — be imposed at the very inception of the process, before any substantive economic negotiations occur. If substantive negotiations take place before the conditions are in place, the MFW framework is unavailable, and the transaction will be reviewed under the entire fairness standard regardless of the subsequent quality of the process.
As applied to the proposed transaction, the timeline presents a nuanced question. Dr. Hale proposed the acquisition on February 14, 2023. The Penterra board discussed potential conflicts on March 8, 2023, and the Special Committee was not formally constituted until June 2, 2023 — approximately three and one-half months after Dr. Hale's initial proposal. This delay raises the question of whether the ab initio condition has been satisfied.
However, we believe the record, properly documented, supports a finding of ab initio compliance for the following reasons. First, Dr. Hale's February 14 proposal was a preliminary expression of interest, not the commencement of substantive economic negotiations. No counter-proposals were exchanged, no term sheets were circulated, and no negotiations regarding price, consideration mix, or other material economic terms occurred between February 14, 2023, and June 2, 2023. The intervening period was devoted to governance process — specifically, the identification and management of conflicts, the engagement of governance counsel (Alcott, Barringer & Cole LLP), and the formation of the Special Committee. Second, the board's March 8, 2023 discussion and its subsequent resolution to consider forming a special committee evidence the board's recognition, at an early stage, that the transaction required special procedural treatment. Third, the Board Resolution adopted on June 2, 2023 expressly conditions any further evaluation and negotiation of the proposed transaction on the approval of the Special Committee, and the stockholder vote structure can be established at this time to satisfy the majority-of-the-minority requirement.
Notwithstanding these favorable facts, the approximately three-and-one-half-month gap between Dr. Hale's initial proposal and the formal constitution of the Special Committee presents some risk. A plaintiff could argue that the delay allowed Dr. Hale or Penterra management to conduct preliminary diligence or form economic expectations that influenced the subsequent negotiation. To mitigate this risk, the Special Committee should take the following steps:
(a) Thoroughly document in the record that no substantive price negotiations or economic discussions occurred prior to June 2, 2023;
(b) Confirm through interviews with relevant personnel (to be conducted by Calderwood & Harkness LLP) that Dr. Hale did not share non-public Caliston information with any Penterra director, officer, or employee other than in the context of his February 14 disclosure and the March 8 board discussion;
(c) Ensure that any Penterra stockholder vote on the share issuance is structured as a majority-of-the-minority vote, excluding Dr. Hale's 2,140,000 Penterra shares from the required majority; and
(d) Insist that Dr. Hale's commitment to the dual-conditioning structure be memorialized in writing — either as an amendment to the existing Voting and Recusal Agreement or in a separate instrument.
Condition 2 — Independence of the Special Committee
The independence of the three Special Committee members — Diane Prescott, James Okafor, and Dr. Helen Ng — has been confirmed through the director independence questionnaire process. Each member satisfies the independence requirements under both NYSE listing standards and Delaware common law. Specifically, none of the three members has any material financial, personal, or professional relationship with Caliston, Dr. Hale, Angela Whitmore, Raymond Tusk, Ridgeline Ventures, LP, Meridian Life Sciences Fund III, LP, or any advisor to Caliston or Dr. Hale.
Calderwood & Harkness LLP has completed its own conflicts clearance, which confirms no conflicts with any party to the transaction. Thorngate Partners LLC has completed a similar clearance. The independence of the Special Committee's advisors reinforces the independence of the Committee itself, as a committee advised by conflicted counsel or a conflicted financial advisor may be deemed to lack the genuine independence required under MFW.
We recommend that the record include a written certification from each Special Committee member confirming his or her independence, and that these certifications be updated if any new relationships or facts come to light during the course of the transaction process.
Condition 3 — Empowerment
The Board Resolution dated June 2, 2023 grants the Special Committee sole and exclusive authority to:
(a) Evaluate the proposed transaction, including the strategic rationale, financial terms, and legal structure;
(b) Negotiate the terms of the transaction, including price, consideration mix, CVR terms, termination fees, representations and warranties, indemnification and escrow provisions, and all other material terms;
(c) Retain and direct independent legal and financial advisors, including Calderwood & Harkness LLP and Thorngate Partners LLC;
(d) Recommend to the full board the approval or rejection of the transaction; and
(e) Explore alternatives to the proposed transaction, including conducting a market check, and to decline the transaction in its sole discretion.
The Special Committee Charter, also effective June 2, 2023, reinforces these authorities and provides for decision-making by majority vote of the three Committee members. The Charter expressly states that the Committee's authority is not subject to the approval or consent of any other director, including Dr. Hale, Ms. Whitmore, or Mr. Tusk.
This scope of authority is consistent with MFW requirements. The critical point, which cannot be overemphasized, is that the Committee's formal authority must not be undermined in practice. If Dr. Hale or any member of Penterra management were to exert informal influence over the Committee's deliberations — for example, by communicating with Committee members outside the formal process, by providing information that was not also made available to the Committee's advisors, or by taking actions designed to foreclose alternatives — the empowerment condition could be deemed unsatisfied. The Information Barrier Policy is designed to prevent such influence, and its compliance should be monitored throughout the process.
Condition 4 — Due Care
The Special Committee must conduct a thorough, informed, and deliberate process in evaluating and negotiating the proposed transaction. This obligation is largely prospective at this stage and will be assessed based on the totality of the Committee's work over the coming months. Specifically, the Committee's duty of care will require:
(a) Independent due diligence on Caliston, including review of clinical data, regulatory filings, financial statements, intellectual property, material contracts, litigation, and employment matters — conducted through the Committee's own advisors rather than through Penterra management;
(b) Engagement and active direction of independent legal counsel (Calderwood & Harkness LLP) and an independent financial advisor (Thorngate Partners LLC);
(c) Receipt and careful consideration of a formal fairness opinion from Thorngate Partners, addressed to the Special Committee;
(d) Genuine arm's-length negotiation of all material transaction terms with Caliston's advisors;
(e) Consideration of alternatives to the proposed transaction, including a market check to determine whether superior acquisition opportunities exist and whether Caliston's assets could be acquired on more favorable terms or from alternative targets;
(f) Regular meetings of the Special Committee, with appropriate documentation in the form of detailed minutes, memoranda, and advisor presentations;
(g) Sufficient time for the Committee to conduct its work without artificial deadlines or pressure from Dr. Hale or Penterra management; and
(h) Appropriate consideration of the risks associated with the transaction, including clinical development risk, regulatory risk, integration risk, and financing risk.
Condition 5 — Informed, Uncoerced Minority Vote
Under NYSE Listed Company Manual rules, Penterra stockholder approval is required for the issuance of 5,903,497 shares of Penterra common stock in connection with the transaction, as this represents significantly more than 1% of Penterra's outstanding shares. This required stockholder vote provides the vehicle through which the majority-of-the-minority condition can be satisfied.
To satisfy MFW Condition 5, the stockholder vote should be structured as a majority-of-the-minority vote, with Dr. Hale's 2,140,000 Penterra shares excluded from the denominator used to calculate the required majority. Dr. Hale's existing Voting and Recusal Agreement, executed on June 2, 2023, provides for his recusal from board-level deliberations and voting; however, it does not expressly address his voting at the stockholder level. We recommend that a supplemental Stockholder Support Agreement be negotiated with Dr. Hale, pursuant to which he would commit either to abstain from voting his Penterra shares on the transaction or to vote his shares in proportion to the votes cast by the disinterested stockholders. Abstention is the cleaner approach and is more commonly employed in practice.
The preliminary proxy statement, to be filed with the SEC following the execution of the merger agreement, must contain full and fair disclosure of all material facts, including:
(a) The nature and extent of Dr. Hale's conflict of interest, including his Caliston equity stake, implied proceeds, and board observer role;
(b) Angela Whitmore's spousal relationship with Dr. Evan Whitmore;
(c) Raymond Tusk's status as a Hale appointee;
(d) The Special Committee's formation, composition, and process;
(e) Thorngate Partners' financial analyses and fairness opinion;
(f) The terms of the proposed merger agreement; and
(g) Any other facts that a reasonable stockholder would consider material in deciding whether to approve the transaction.
The Company may wish to retain Hargrove Proxy Advisors, Inc. to assist with stockholder outreach and proxy solicitation, particularly given the importance of securing a robust majority-of-the-minority vote.
Condition 6 — No Structural Coercion
The Special Committee should ensure that the transaction structure does not coerce minority stockholders into approving the deal. Structural coercion can take various forms, including implicit threats that the interested party will take adverse action if the transaction is not approved, or features of the transaction that impose disproportionate burdens on stockholders who vote against the deal.
In the present context, the risk of structural coercion is mitigated by several factors. First, this is an acquisition of a third-party target rather than a going-private or squeeze-out transaction, which means that Penterra stockholders are not being cashed out of their investment or forced to accept a change in the nature of their equity interest. Second, the mixed consideration structure (75% cash / 25% stock) does not create the type of coercive dynamics that can arise in all-stock transactions where the interested party's continuing equity interest creates divergent incentives. Third, the absence of a squeeze-out mechanism means that there is no structural penalty for stockholders who vote against the transaction.
However, to the extent that Dr. Hale's continued role as Penterra's Chairman and CEO creates implicit pressure — for example, concerns among stockholders that voting against the deal could adversely affect the Company's leadership stability or that Dr. Hale might retaliate against the Company — the process should be documented to demonstrate that the Special Committee operated independently and that no such implicit threats were made. The Voting and Recusal Agreement and the Information Barrier Policy are important safeguards in this regard, and their continued enforcement should be monitored.
D. Consequences of Satisfying vs. Failing MFW
The consequences of satisfying or failing to satisfy the MFW framework are substantial and directly affect the litigation risk profile of the transaction:
If all six MFW conditions are met: Business judgment review applies. The plaintiff bears the heavy burden of demonstrating that the transaction constituted waste, was approved in bad faith, or involved a disabling conflict that was not adequately addressed by the procedural protections. As a practical matter, transactions reviewed under the business judgment standard are virtually unassailable absent egregious facts, and motions to dismiss filed at the pleading stage are frequently granted.
If any single MFW condition is not met: The entire fairness standard remains the applicable standard of review. In this scenario, the allocation of the burden of proof depends on whether at least one procedural protection — either an independent committee or a majority-of-the-minority vote — was employed:
• If neither procedural protection was employed, the burden of proving entire fairness rests on the defendant directors.
• If the transaction was approved by a well-functioning independent committee or by an informed, uncoerced majority-of-the-minority vote, the burden of proving that the transaction was not entirely fair shifts to the plaintiff. This burden shifting is meaningful but does not change the standard of review; the court still applies entire fairness analysis.
Even if the MFW framework is not fully satisfied — for example, due to a deficiency in the ab initio conditioning requirement — the use of a properly functioning Special Committee with genuine independence, empowerment, and procedural rigor will provide the strongest possible defense under the entire fairness standard and will shift the burden of proof to any plaintiff challenging the transaction.
VI. Specific Issues Requiring Attention
A. Dr. Hale's Delayed Disclosure
Dr. Hale did not disclose his 28.5% equity interest in Caliston to the Penterra board of directors until February 14, 2023 — the same date on which he first proposed the acquisition. This is notable because Dr. Hale acquired his Caliston interest through investments in the Seed, Series A, and Series B financing rounds and has served as a non-voting board observer at Caliston since 2018. Throughout this period, he did not inform the Penterra board of his investment in a company that operates in the same therapeutic area (oncology) as Penterra and that could reasonably be expected to be a potential acquisition target.
This delayed disclosure is concerning from a governance standpoint and could be seized upon by a plaintiff as evidence that Dr. Hale sought to conceal his interest until the time was opportune for him to propose the transaction. A plaintiff might argue that the delay evidences bad faith, self-dealing, or an attempt to circumvent the board's oversight of related-party transactions. The failure to disclose also raises questions about whether Penterra's existing corporate governance policies — including its related-party transaction policy and director questionnaire process — were adequate or were complied with.
However, for purposes of the standard of review analysis, it is the Special Committee's process going forward that will be most material. Delaware courts have recognized that the existence of a conflict does not, by itself, render a transaction unfair; what matters is whether the conflict was adequately managed through proper procedural protections. The Special Committee's establishment, its independence, and the rigor of its process are the factors that will most heavily influence the court's assessment.
We recommend that the record reflect that the Special Committee was fully aware of Dr. Hale's delayed disclosure and that it factored this delay into its overall assessment of the transaction process, including the need for heightened vigilance regarding information asymmetries and the importance of independent due diligence.
B. Angela Whitmore / Dr. Evan Whitmore Spousal Relationship
Angela Whitmore's conflict is derivative of her spousal relationship with Dr. Evan Whitmore but is nonetheless material. Dr. Evan Whitmore serves in a senior executive role at Caliston (Head of Clinical Development) and sits on the Caliston board of directors. He holds an equity interest in Caliston through the management equity pool and stands to receive merger consideration in connection with the proposed transaction. Additionally, the proposed transaction would make him a Penterra employee post-closing, potentially subject to employment agreements and equity arrangements that have not yet been negotiated.
Ms. Whitmore's exclusion from the Special Committee and from all board deliberations concerning the transaction — alongside Dr. Hale and Mr. Tusk — was implemented through the June 2, 2023 Board Resolution and the Information Barrier Policy. This exclusion is necessary and appropriate. Delaware courts have consistently held that the existence of close familial relationships, and spousal relationships in particular, can compromise a director's independence and ability to exercise impartial judgment. See Beam v. Stewart, 845 A.2d at 1050-52; In re Ridgeline Industries, 824 A.2d at 937-38.
The Whitmore spousal relationship should be prominently disclosed in the proxy statement, including Dr. Evan Whitmore's roles at Caliston, his equity interest, and the potential for his continued employment with the surviving entity post-closing. Failure to disclose this relationship could give rise to a disclosure claim under Delaware law.
C. Raymond Tusk — Hale Appointee
Raymond Tusk has been classified as non-independent due to his status as a director appointed by Dr. Hale. While Mr. Tusk does not hold any direct financial interest in Caliston, his personal and professional relationship with Dr. Hale — including the circumstances of his board appointment — means that he cannot be considered independent of Dr. Hale for purposes of evaluating the proposed transaction.